Sky's James Sillars writes that a government, struggling for authority and prioritising economic growth, can not afford to ...

AstraZeneca sold its West Chester site 8814 Trade Port Drive for $212 million.

AstraZeneca is building out manufacturing capacity to manage turbulent geopolitical times.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make ...

AstraZeneca (AZN, Financials) is weighing a move from London to a U.S. stock exchange; a shift that would mark a blow to the ...

AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts the Truqap trial in prostate cancer.

CAMBRIDGE, Britain (AP) — CAMBRIDGE, Britain (AP) — Astrazeneca PLC (AZN) on Tuesday reported first-quarter profit of $2.92 billion. On a per-share basis, the Cambridge, Britain-based company ...

UK-based biopharmaceutical company AstraZeneca has announced a $3.5bn investment to expand its research and manufacturing capabilities in the US.

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition. Find out why AZN stock is a hold.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company ...

AstraZeneca is investing $2.5bn in research and development and manufacturing in Beijing, as the drugmaker tries to move on after a scandal that led to the detention of a top executive in China.

AstraZeneca disclosed that a high-ranking executive who oversees international operations and is also president of its subsidiary in China is under investigation by Chinese authorities.